Breaking News

LOTTE Biologics, Ottimo Pharma Sign Antibody Manufacturing Contract 

LOTTE will produce antibody drug substance for Ottimo Pharma's Jankistomig at its Syracuse, NY Bio Campus.

LOTTE BIOLOGICS has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a biopharmaceutical company developing first-in-class, PD1/VEGFR2 dual pathway antibodies to treat cancer. LOTTE BIOLOGICS will produce antibody drug substance for Ottimo Pharma’s Jankistomig at its Syracuse Bio Campus in New York. James Park, CEO of LOTTE BIOLOGICS, stated, “This agreement serves as further validation of our competitiveness as a CDMO in the global antibo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters